Beijing Konruns Pharmaceutical603590.SHValuation Analysis

As of Oct 19, 2026, Beijing Konruns Pharmaceutical (603590.SH) trades at a P/E of 25.80x, P/B of 1.39x, P/S of 4.76x, and a dividend yield of 1.25%.
Longitudinal percentile comparison: P/E sits at the 23rd percentile over the trailing 10Y window (vs. 5th percentile over 3Y); P/B sits at the 14th percentile over the trailing 10Y window (vs. 27th percentile over 3Y); P/S sits at the 9th percentile over the trailing 10Y window (vs. 21st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 33rd percentile within its industry and the 35th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.71%, ranking at the 70th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 8.6 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 1.25% comes from cash dividends, with an implied ~0.46% from buybacks — a fairly balanced mix of both channels. Beijing Konruns Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.